All Stories

  1. MYC as a Target for Cancer Treatment: from Undruggable to Druggable?

    Article • Targeted Oncology, August 2025, Springer Science + Business Media

    Dr Michael J Duffy

  2. Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer

    Article • Translational Oncology, August 2024, Elsevier

    Dr Michael J Duffy

  3. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction

    Article • Tumor Biology, March 2024, IOS Press

    Dr Michael J Duffy

  4. Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells

    Article • Investigational New Drugs, May 2023, Springer Science + Business Media

    Dr Michael J Duffy

  5. Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?

    Article • Nutrition and Cancer, December 2022, Taylor & Francis

    Dr Michael J Duffy

  6. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

    Article • Cancers, September 2022, MDPI AG

    Dr Michael J Duffy

  7. Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers

    Article • Clinical Chemistry, August 2022, Oxford University Press (OUP)

    Dr Michael J Duffy

  8. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

    Article • Breast Cancer Research and Treatment, July 2022, Springer Science + Business Media

    Dr Michael J Duffy

  9. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells

    Article • Medical Oncology, July 2022, Springer Science + Business Media

    Dr Michael J Duffy

  10. Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer

    Article • Journal of Personalized Medicine, January 2022, MDPI AG

    Dr Michael J Duffy

  11. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), April 2021, De Gruyter

    Dr Michael J Duffy

  12. MYC as a target for cancer treatment

    Article • Cancer Treatment Reviews, March 2021, Elsevier

    Dr Michael J Duffy

  13. Targeting p53 for the treatment of cancer

    Article • Seminars in Cancer Biology, July 2020, Elsevier

    Dr Michael J Duffy

  14. Biomarkers for prostate cancer: prostate-specific antigen and beyond

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2019, De Gruyter

    Dr Michael J Duffy

  15. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

    Article • Breast Cancer Research and Treatment, September 2019, Springer Science + Business Media

    Dr Michael J Duffy

  16. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients

    Article • Clinical Chemistry, July 2019, AACC

    Dr Michael J Duffy

  17. MYC as a therapeutic target for the treatment of triple-negative breast cancer.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Dr Michael J Duffy

  18. An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer

    Article • Cancer Management and Research, December 2018, Dove Medical Press

    Dr Michael J Duffy

  19. Circulating tumour DNA as a cancer biomarker

    Article • Annals of Clinical Biochemistry International Journal of Laboratory Medicine, September 2018, SAGE Publications

    Dr Michael J Duffy

  20. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA

    Article • Tumor Biology, April 2018, SAGE Publications

    Dr Michael J Duffy

  21. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

    Article • Cancer Letters, February 2018, Elsevier

    Dr Michael J Duffy

  22. Mutant p53 as a target for cancer treatment

    Article • European Journal of Cancer, September 2017, Elsevier

    Dr Michael J Duffy

  23. Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Dr Michael J Duffy

  24. Vitamin D analogues: Potential use in cancer treatment

    Article • Critical Reviews in Oncology/Hematology, April 2017, Elsevier

    Dr Michael J Duffy

  25. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

    Article • European Journal of Cancer, April 2017, Elsevier

    Dr Michael J Duffy

  26. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy

    Article • Clinical Chemistry, February 2017, AACC

    Dr Michael J Duffy

  27. p53 in cancer: ready for therapeutic targeting?

    Article • Translational Cancer Research, December 2016, AME Publishing Company

    Dr Michael J Duffy

  28. A new drug for targeting mutant p53 in breast cancer

    Article • International Journal of Cancer, September 2016, Wiley

    Dr Michael J Duffy

  29. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246.

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Dr Michael J Duffy

  30. Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers

    Article • Clinical Chemistry, April 2015, AACC

    Dr Michael J Duffy

  31. Personalized treatment for patients with colorectal cancer: role of biomarkers

    Article • Biomarkers in Medicine, March 2015, Future Medicine

    Dr Michael J Duffy

  32. Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

    Article • Laboratory Medicine Online, January 2015, Korean Society for Laboratory Medicine (KAMJE)

    Dr Michael J Duffy

  33. Use of Biomarkers in Screening for Cancer

    Article • January 2015, Springer Science + Business Media

    Dr Michael J Duffy

  34. Biomarkers in Breast Cancer

    Article • January 2015, Elsevier

    Dr Michael J Duffy

  35. p53 as a target for the treatment of cancer

    Article • Cancer Treatment Reviews, December 2014, Elsevier

    Dr Michael J Duffy

  36. Personalised treatment for cancer: role of biomarkers

    Article • The EPMA Journal, February 2014, Springer Science + Business Media

    Dr Michael J Duffy

  37. PSA in Screening for Prostate Cancer

    Article • January 2014, Elsevier

    Dr Michael J Duffy

  38. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update

    Article • International Journal of Cancer, August 2013, Wiley

    Dr Michael J Duffy

  39. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

    Article • Cancer Biology & Therapy, June 2013, Taylor & Francis

    Dr Michael J Duffy

  40. Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

    Article • Clinical Chemistry, May 2013, Oxford University Press (OUP)

    Dr Michael J Duffy

  41. The war on cancer: are we winning?

    Article • Tumor Biology, April 2013, Springer Science + Business Media

    Dr Michael J Duffy

  42. The ADAMs: New Therapeutic Targets for Cancer?

    Article • January 2013, Springer Science + Business Media

    Dr Michael J Duffy

  43. 558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer

    Article • European Journal of Cancer, November 2012, Elsevier

    Dr Michael J Duffy

  44. 304 Notch in Breast Cancer: Preclinical and Clinical Studies

    Article • European Journal of Cancer, November 2012, Elsevier

    Dr Michael J Duffy

  45. 305 Notch 4: a Paradoxical Role in Breast Cancer Progression?

    Article • European Journal of Cancer, November 2012, Elsevier

    Dr Michael J Duffy

  46. Targeted therapy for triple-negative breast cancer: Where are we?

    Article • International Journal of Cancer, June 2012, Wiley

    Dr Michael J Duffy

  47. mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors

    Article • The Breast, April 2012, Elsevier

    Dr Michael J Duffy

  48. P3-17-03: ADAM17: A Novel Therapeutic Target for Treatment of Triple Negative Breast Cancer.

    Article • Cancer Research, December 2011, American Association for Cancer Research (AACR)

    Dr Michael J Duffy

  49. BRMS1 (breast cancer metastasis suppressor 1)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011, INIST-CNRS

    Dr Michael J Duffy

  50. ETS2 (v-ets erythroblastosis virus E26 oncogene homolog 2 (avian))

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011, INIST-CNRS

    Dr Michael J Duffy

  51. 1092 POSTER Trastuzumab Binds to HER2 Non-amplified Breast Cancer Cells and Induces ADCC

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Michael J Duffy

  52. Use of molecular markers for predicting therapy response in cancer patients

    Article • Cancer Treatment Reviews, April 2011, Elsevier

    Dr Michael J Duffy

  53. Intracellular and Extracellular MicroRNAs in Breast Cancer

    Article • Clinical Chemistry, November 2010, Oxford University Press (OUP)

    Dr Michael J Duffy

  54. 129 ADAM17: A new therapeutic target for triple negative breast cancer?

    Article • European Journal of Cancer Supplements, November 2010, Elsevier

    Dr Michael J Duffy

  55. Survivin: A new target for anti-cancer therapy

    Article • Cancer Treatment Reviews, November 2009, Elsevier

    Dr Michael J Duffy

  56. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

    Article • Annals of Oncology, August 2009, Oxford University Press (OUP)

    Dr Michael J Duffy

  57. Role of ADAMs in Cancer Formation and Progression

    Article • Clinical Cancer Research, February 2009, American Association for Cancer Research (AACR)

    Dr Michael J Duffy

  58. Biomarkers in oncology

    Article • February 2009, Taylor & Francis

    Dr Michael J Duffy

  59. Methylated genes as new cancer biomarkers

    Article • European Journal of Cancer, February 2009, Elsevier

    Dr Michael J Duffy

  60. The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.

    Article • Cancer Research, January 2009, American Association for Cancer Research (AACR)

    Dr Michael J Duffy

  61. A Personalized Approach to Cancer Treatment: How Biomarkers Can Help

    Article • Clinical Chemistry, November 2008, Oxford University Press (OUP)

    Dr Michael J Duffy

  62. Tumor markers in breast cancer – european group on tumor markers (EGTM) recommendations

    Article • Biomedicine & Pharmacotherapy, October 2008, Elsevier

    Dr Michael J Duffy

  63. Cancer invasion and metastasis: changing views

    Article • The Journal of Pathology, December 2007, Wiley

    Dr Michael J Duffy

  64. Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression

    Article • Clinical Cancer Research, November 2007, American Association for Cancer Research (AACR)

    Dr Michael J Duffy

  65. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use

    Article • European Journal of Cancer, June 2007, Elsevier

    Dr Michael J Duffy

  66. ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression

    Article • Clinical Cancer Research, April 2007, American Association for Cancer Research (AACR)

    Dr Michael J Duffy

  67. Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer

    Article • International Journal of Cancer, December 2006, Wiley

    Dr Michael J Duffy

  68. P14. ADAM-17: A mediator of breast cancer progression?

    Article • European Journal of Cancer Supplements, June 2006, Elsevier

    Dr Michael J Duffy

  69. uPA and PAI-1: Clinically and technically validated prognostic markers in breast cancer

    Article • European Journal of Cancer Supplements, June 2006, Elsevier

    Dr Michael J Duffy

  70. Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?

    Article • Clinical Chemistry, March 2006, Oxford University Press (OUP)

    Dr Michael J Duffy

  71. Computerising a rapid breast clinic

    Article • European Journal of Cancer Supplements, March 2006, Elsevier

    Dr Michael J Duffy

  72. Urokinase-Type Plasminogen Activator and PAI-1

    Article • January 2006, Springer Science + Business Media

    Dr Michael J Duffy

  73. Estrogen Receptors in Breast Cancer

    Article • Critical Reviews in Clinical Laboratory Sciences, January 2006, Taylor & Francis

    Dr Michael J Duffy

  74. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

    Article • International Journal of Gynecological Cancer, September 2005, Wolters Kluwer Health

    Dr Michael J Duffy

  75. Predictive Markers in Breast and Other Cancers: A Review

    Article • Clinical Chemistry, March 2005, AACC

    Dr Michael J Duffy

  76. Mammaglobin a in breast cancer: Existence of multiple molecular forms

    Article • International Journal of Cancer, January 2005, Wiley

    Dr Michael J Duffy

  77. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer

    Article • Clinical Biochemistry, July 2004, Elsevier

    Dr Michael J Duffy

  78. The Urokinase Plasminogen Activator System: Role in Malignancy

    Article • Current Pharmaceutical Design, January 2004, Bentham Science Publishers

    Dr Michael J Duffy

  79. Expression of ADAM-9 mRNA and protein in human breast cancer

    Article • International Journal of Cancer, May 2003, Wiley

    Dr Michael J Duffy

  80. Urokinase plasminogen activator, a potent marker of metastatic potential in human cancer

    Article • Biochemical Society Transactions, February 2002, Portland Press Ltd.

    Dr Michael J Duffy

  81. Biochemical markers in breast cancer: which ones are clinically useful?

    Article • Clinical Biochemistry, July 2001, Elsevier

    Dr Michael J Duffy

  82. Studies on oestrogen receptor-α and -β mRNA in breast cancer

    Article • European Journal of Cancer, June 2001, Elsevier

    Dr Michael J Duffy

  83. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis

    Article • August 2000, Springer Science + Business Media

    Dr Michael J Duffy

  84. High levels of TIMP-2 correlate with adverse prognosis in breast cancer

    Article • International Journal of Cancer, March 2000, Wiley

    Dr Michael J Duffy

  85. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin

    Article • International Journal of Cancer, February 2000, Wiley

    Dr Michael J Duffy

  86. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skinT. Maguire and D. Chin contributed equally to this work.

    Article • International Journal of Cancer, February 2000, Wiley

    Dr Michael J Duffy

  87. Estrogen receptor-beta: a new form of estrogen receptor in breast cancer

    Article • European Journal of Cancer, September 1999, Elsevier

    Dr Michael J Duffy

  88. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer

    Article • Journal of Surgical Oncology, June 1999, Wiley

    Dr Michael J Duffy

  89. High levels of tissue inhibitor of metalloproteinase‐1 predict poor outcome in patients with breast cancer

    Article • International Journal of Cancer, February 1999, Wiley

    Dr Michael J Duffy

  90. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

    Article • British Journal of Cancer, December 1998, Nature

    Dr Michael J Duffy

  91. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).

    Article • International Journal of Oncology, June 1998, Spandidos Publications

    Dr Michael J Duffy

  92. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry

    Article • British Journal of Cancer, May 1998, Nature

    Dr Michael J Duffy

  93. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer

    Article • British Journal of Cancer, March 1998, Nature

    Dr Michael J Duffy

  94. Cancer metastasis: Biological and clinical aspects

    Article • Irish Journal of Medical Science (1971 -), January 1998, Springer Science + Business Media

    Dr Michael J Duffy

  95. Re: Urokinase and Urokinase Receptor: Association With In Vitro Invasiveness of Human Bladder Cancer Cell Lines

    Article • JNCI Journal of the National Cancer Institute, November 1997, Oxford University Press (OUP)

    Dr Michael J Duffy

  96. Clinical significance of urokinase plasminogen activator and it receptor in breast cancer

    Article • European Journal of Cancer, September 1997, Elsevier

    Dr Michael J Duffy

  97. Plasminogen activator inhibitor type 2 in breast cancer

    Article • British Journal of Cancer, September 1997, Nature

    Dr Michael J Duffy

  98. The urokinase-type plasminogen activator system in cancer metastasis: A review

    Article • International Journal of Cancer, July 1997, Wiley

    Dr Michael J Duffy

  99. The Biochemistry of Metastasis

    Article • January 1996, Elsevier

    Dr Michael J Duffy

  100. 662 Urokinase plasminogen activator, a potential prognostic marker for node-negative breast cancer

    Article • European Journal of Cancer, November 1995, Elsevier

    Dr Michael J Duffy

  101. 680 CA 15-3 predicts outcome in breast cancer patients

    Article • European Journal of Cancer, November 1995, Elsevier

    Dr Michael J Duffy

  102. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

    Article • International Journal of Cancer, May 1995, Wiley

    Dr Michael J Duffy

  103. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer

    Article • British Journal of Cancer, May 1995, Nature

    Dr Michael J Duffy

  104. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer

    Article • Cancer, October 1994, Wiley

    Dr Michael J Duffy

  105. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer

    Article • The Lancet, August 1994, Elsevier

    Dr Michael J Duffy

  106. Cellular oncogenes and suppressor genes as prognostic markers in cancer

    Article • Clinical Biochemistry, December 1993, Elsevier

    Dr Michael J Duffy

  107. The role of proteolytic enzymes in cancer invasion and metastasis

    Article • Clinical & Experimental Metastasis, May 1992, Springer Science + Business Media

    Dr Michael J Duffy

  108. Type-1 plasminogen activator inhibitor in human breast carcinomas

    Article • International Journal of Cancer, January 1992, Wiley

    Dr Michael J Duffy

  109. Inhibiting tissue invasion and metastasis as targets for cancer therapy

    Article • Biotherapy, January 1992, Springer Science + Business Media

    Dr Michael J Duffy

  110. Urokinase-plasminogen activator in breast cancer

    Article • Blood Coagulation & Fibrinolysis, February 1991, Wolters Kluwer Health

    Dr Michael J Duffy

  111. Urokinase plasminogen activator and prognosis in breast cancer

    Article • The Lancet, January 1990, Elsevier

    Dr Michael J Duffy

  112. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

    Article • Cancer, August 1988, Wiley

    Dr Michael J Duffy

  113. Do proteases play a role in cancer invasion and metastasis?

    Article • European Journal of Cancer and Clinical Oncology, May 1987, Elsevier

    Dr Michael J Duffy

  114. A Biochemical approach to cancer management

    Article • Irish Journal of Medical Science (1971 -), September 1984, Springer Science + Business Media

    Dr Michael J Duffy

  115. Plasma concentrations of the platelet-specific β-thromboglobulin in malignant disease

    Article • British Journal of Cancer, June 1980, Nature

    Dr Michael J Duffy

  116. Studies on progesterone receptors in human breast carcinomas: Use of natural and synthetic ligands

    Article • European Journal of Cancer (1965), October 1979, Elsevier

    Dr Michael J Duffy

  117. New Tumor Biomarkers

    Article • Springer Science + Business Media

    Dr Michael J Duffy